Ignite Creation Date:
2025-12-25 @ 4:35 AM
Ignite Modification Date:
2026-03-09 @ 11:22 AM
Study NCT ID:
NCT06984718
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-05-22
First Post:
2025-05-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC
Sponsor:
Akeso
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
AK104-225
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None